MedCalX

54
MedCalX
MedCalX is an iOS app from Ossus GmbH in the Education category, currently rated 3.7★ across 29 ratings. Initial signal reads as mixed reviews: supporters praise core features while critics cite stability and value gaps.
Quality Score is 54: Solid (established niche player). For a Education app, that means established niche player. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
📊 Performance Tracking LIVE
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Education complexity ×1.20 | +$10K |
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
| 📺 Ad-supported base | 15× MRR |
| ⭐ ★ rating 3.5-4.0 (mixed) | -8% |
| 🏷 Education category multiple | +6% |
| ⭐ Small user base (<1K ratings) | -8% |
How we forecast this revenue
LOW CONFIDENCEBU Investment Matrix
Insufficient data · 39/100MICRO TIERtoo early to score- 💰 Revenue: Marginal — $0 - $500/mo · MICRO tier · indicative confidence, trajectory unclear.
- ⭐ Quality: 3.69★ across 29 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: last update 216d ago — slow cadence.
- ⚠️ Risk: Low — no material risk signals detected.
💰 Forecast Revenue / mo
MODEL| Paid app ($0.00)METRIC | +$2,800 | |
| 5 starREVIEW | +$1,800 | |
| excellent appREVIEW | +$1,500 | |
| Mature app (10y old)METRIC | +$1,500 | |
| Localized (6 languages)METRIC | +$600 | |
| Pre-traction phase (29 ratings)METRIC | −$300 |
📈 Reviews Growth
LIVE⭐ Rating Trend
LIVE🆕 What's New · v3.5.2
• Remembers purchases better
• Fix full screen image view in workflows & Snellen
• Smaller fixes & improvements
Profile & Insights
Identification
- App name
- MedCalX
- Developer
- Ossus GmbH
- Bundle ID
- ch.ossus.medcalx.ios
- App Store URL
- Open in App Store
- Category
- Education
- Content rating
- 17+
- Languages
- EN, FR, DE, PT, ZH, ES
Company
- Website
- Not found
- Tagline
- Today
- Description
- Find apps and games for iPhone, iPad, Mac, and more on the App Store.
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Available
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $19.1K/mo
- Top-grossing rank
- Outside top 100 in US Education
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Funding
Press & Links
Contacts & Socials
📈Ratings growth29 ratings+2800% lifetimeShow 3-year history estimate ▾
📝 About this app
25 years of experience developing this tool for mobile platforms makes MedCalX the leading medical calculator, with an unparalleled user interface and powerful features.
MedCalX is free to download and use, but you have access only to a subset of formulas.
In-app purchase lets you unlock the whole range of formulas that MedCalX has to offer; more than 300 in total!
Main features:… View full description on the official store →
What Worked™ · Development Pipeline
6 EVENTS TRACKEDTrack this app’s revenue
FREE📝 Description
95
More by Ossus GmbH
View all →Why low confidence: only 29 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
MedCalX is a small / niche iOS app in the education space with weak public traction — only 29 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.




